Atazanavir Twice Daily

Completed · Phase 1

Conditions studied: HIV Infections, Protease Inhibitor

In brief

The purpose of this clinical research study is to assess the pharmacokinetics of atazanavir administered twice-daily relative to historical data from atazanavir/ritonavir 300/100 mg, given once daily.

Key facts

Study ID

NCT00357721

Run by

Bristol-Myers Squibb

People needed

18

Starts

2006-06-01

Expected to finish

2006-09-01

Last updated by the study team

2011-04-06

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy male and female subjects between the ages of 18 to 45 years old with a BMI of 18 to 30 kg/m2

Where it is running

• Local Institution — Hamilton, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.